AK and miltefosine
Three weeks after treatment with oral miltefosine offers promising hope for patients with AK. Miltefosine is not yet approved for AK but has received orphan drug designation.
top of page
Featured Posts
Recent Posts
Archive
Search By Tags
Follow Us
Impavido® (miltefosine) is an FDA-approved treatment for cutaneous, mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO
bottom of page